封面
市场调查报告书
商品编码
1672928

Telmisartan市场:依成分、适应症、剂型、通路和地区划分

Telmisartan Market, By Composition, By Indication, By Dosage Form, By Distribution Channel, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 157 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2025 年全球Telmisartan市场规模估计为 43.6 亿美元,预计到 2032 年将达到 57.1 亿美元,2025 年至 2032 年的年复合成长率(CAGR)为 3.9%。

报告范围 报告详细信息
基准年 2024 2025 年市场规模 43.6亿美元
效能资料 2020-2024 预测期 2025-2032
预测期:2025 年至 2032 年复合年增长率 3.90% 2032 年金额预测 57.1亿美元
数字。 2025 年Telmisartan各地区市场占有率(%)
替米沙坦市场-IMG1

Telmisartan为血管收缩素素II受体拮抗剂,主要用于治疗高血压、糖尿病肾臟病。该药物透过选择性抑制血管收缩素II 与血管平滑肌和肾上腺中的 AT1 受体结合发挥作用。Telmisartan可透过抑制血管收缩素II 的血管收缩和醛固酮分泌作用来降低血压。Telmisartan是一种口服药物,以多种商品名出售,其安全性已通过长期临床试验得到证实。人们对心血管健康的认识不断提高以及高血压盛行率的上升可能会推动全球Telmisartan市场的成长。

市场动态

全球Telmisartan市场的成长受到人口快速老化、全球高血压盛行率上升、肥胖导致久坐生活方式增加以及新兴国家医疗保健支出增加等因素的推动。然而,学名药药的出现以及主要品牌专利到期可能会给市场相关人员带来挑战。持续研究扩大Telmisartan的治疗用途,并进行临床试验以评估其在治疗高血压以外的疾病方面的有效性,这可能会在不久的将来为相关人员提供机会。与开发中国家的当地分销网络合作​​也提供了一个利用未满足需求的有吸引力的途径。

研究的主要特点

  • 本报告对全球Telmisartan市场进行了详细分析,并以 2024 年为基准年,展示了预测期(2025-2032 年)的市场规模和年复合成长率(CAGR%)。
  • 它还强调了各个领域的潜在商机,并说明了该市场的引人注目的投资提案矩阵。
  • 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
  • 它根据公司亮点、产品系列、关键亮点、绩效和策略等参数,介绍了全球Telmisartan市场的主要企业概况。
  • 本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
  • 全球Telmisartan市场报告针对该行业的各个相关人员,例如投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
  • 相关人员将透过全球Telmisartan市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 影响分析
  • 市场趋势
  • 监管情景
  • 收购和合作场景
  • 资金筹措和投资
  • PEST分析
  • 波特的分析

4. 全球Telmisartan市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 整体影响
  • 政府倡议
  • COVID-19 市场影响

5. 2020 年至 2032 年全球Telmisartan市场(按配方划分)(十亿美元)

  • 介绍
  • 单身的
  • 组合

第 6 章。 2020 年至 2032 年Telmisartan全球市场(按适应症划分)(十亿美元)

  • 介绍
  • 高血压
  • 肾臟病
  • 肝肾症候群
  • 心臟麻痹
  • 中风

第 7 章。 2020-2032 年全球Telmisartan市场(以剂型划分)(十亿美元)

  • 介绍
  • 锭剂
  • 胶囊
  • 注射
  • 口服悬浮液

8. 2020-2032 年全球Telmisartan市场按分销管道划分(十亿美元)

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局

9. 2020 年至 2032 年全球Telmisartan市场(按地区划分)(十亿美元)

  • 介绍
  • 北美洲
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第十章 竞争格局

  • 公司简介
    • Boehringer Ingelheim GmbH
    • Glenmark Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Aurobindo Pharma
    • Sun Pharmaceutical Industries Ltd.
    • Mylan NV
    • Cipla Ltd.
    • Abbott Laboratories
    • Cadila Healthcare Ltd
    • Torrent Pharmaceuticals Ltd.
    • Merck KGaA
    • Pfizer Inc.
    • Sanofi SA
    • Bayer AG
    • AstraZeneca PLC
    • Daiichi Sankyo Company, Limited
    • Macleods Pharmaceuticals Ltd.

第 11 章 分析师建议

  • 兴衰
  • 一致的机会地图

第 12 章参考文献与调查方法

  • 参考
  • 调查方法
简介目录
Product Code: CMI2524

Global Telmisartan Market is estimated to be valued at USD 4.36 Bn in 2025 and is expected to reach USD 5.71 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 4.36 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 3.90% 2032 Value Projection: USD 5.71 Bn
Figure. Telmisartan Market Share (%), By Region 2025
Telmisartan Market - IMG1

Telmisartan is an angiotensin II receptor antagonist that is used primarily in the treatment of hypertension and diabetic nephropathy. It works by selectively blocking the binding of angiotensin II to the AT1 receptors present in vascular smooth muscle and the adrenal glands. By blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II, telmisartan helps lower blood pressure. It is available under various brand names as an oral medication and has a well-established safety profile supported by long-term clinical trials. Growing awareness about cardiovascular health and increasing prevalence of hypertension can drive the global telmisartan market growth.

Market Dynamics:

Global telmisartan market growth is driven by factors such as rapidly aging population, rising prevalence of hypertension worldwide, increasing adoption of sedentary lifestyle resulting in obesity, and growing healthcare expenditure in emerging nations. However, availability of generic substitutes and patent expiration of major brands can pose challenges for market players. Continuous research on expanding therapeutic applications of telmisartan and ongoing clinical trials evaluating its efficacy in treatment of conditions beyond hypertension can offer opportunities for stakeholders in the near future. Partnerships with local distribution networks in developing countries also provide an attractive avenue for leveraging unmet demand.

Key Features of the Study:

  • This report provides in-depth analysis of the global telmisartan market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global telmisartan market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include, Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Abbott Laboratories, Cadila Healthcare Ltd, Torrent Pharmaceuticals Ltd., Merck KGaA, Pfizer Inc., Sanofi S.A., Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Macleods Pharmaceuticals Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global telmisartan market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global telmisartan market

Detailed Segmentation-

  • By Composition
    • Single
    • Combinational
  • By Indication
    • Hypertension
    • Nephropathy
    • Hepatorenal Syndrome
    • Cardiac Arrest
    • Stroke
  • By Dosage Form
    • Tablets
    • Capsules
    • Injection
    • Oral suspension
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Boehringer Ingelheim GmbH
    • Glenmark Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • Aurobindo Pharma
    • Sun Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Cipla Ltd.
    • Abbott Laboratories
    • Cadila Healthcare Ltd
    • Torrent Pharmaceuticals Ltd.
    • Merck KGaA
    • Pfizer Inc.
    • Sanofi S.A.
    • Bayer AG
    • AstraZeneca PLC
    • Daiichi Sankyo Company, Limited
    • Macleods Pharmaceuticals Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Composition
    • Market Snapshot, By Indication
    • Market Snapshot, By Dosage Form
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Telmisartan Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Telmisartan Market, By Composition, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Single
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Combinational
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Telmisartan Market, By Indication 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Hypertension
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Nephropathy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hepatorenal Syndrome
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Cardiac Arrest
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Stroke
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Telmisartan Market, By Dosage Form, 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Tablets
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Capsules
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Injection
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Oral suspension
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Telmisartan Market, By Distribution Channel 2020 - 2032, (USD Bn)

  • Overview
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2020 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Telmisartan Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2032
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2020 - 2032, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Company Profiles
    • Boehringer Ingelheim GmbH
      • Company Highlights
      • Composition Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Glenmark Pharmaceuticals Ltd.
      • Company Highlights
      • Composition Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Composition Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sandoz International GmbH
      • Company Highlights
      • Composition Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Aurobindo Pharma
      • Company Highlights
      • Composition Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sun Pharmaceutical Industries Ltd.
      • Company Highlights
      • Composition Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Mylan N.V.
    • Cipla Ltd.
    • Abbott Laboratories
    • Cadila Healthcare Ltd
    • Torrent Pharmaceuticals Ltd.
    • Merck KGaA
    • Pfizer Inc.
    • Sanofi S.A.
    • Bayer AG
    • AstraZeneca PLC
    • Daiichi Sankyo Company, Limited
    • Macleods Pharmaceuticals Ltd.

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact